Friday, February 21, 2025
20.1 C
Delhi

Tag: HUTCHMED

HUTCHMED Announces NMPA Full Approval for ORPATHYS ® ( savolitinib) in China for Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC –...

This web site aggregates information articles from varied sources for informational functions. We don't declare possession of the...

HUTCHMED Announces US$ 608 million Divestment of Non-Core Joint Venture – London Stock Exchange News Today

This web site aggregates information articles from numerous sources for informational functions. We don't declare possession of the...

HUTCHMED Announces Launch by Takeda of FRUZAQLA ® (fruquintinib) in Japan – London Stock Exchange News Today

This web site aggregates information articles from varied sources for informational functions. We don't declare possession of the...

HUTCHMED Highlights Clinical Data to be Presented at ESMO Congress 2024 and the 2024 World Conference of Lung Cancer – London Stock Exchange News...

This web site aggregates information articles from numerous sources for informational functions. We don't declare possession of the...

HUTCHMED Provides Update on Fruquintinib for Second-Line Gastric Cancer in China – London Stock Exchange News Today

This web site aggregates information articles from varied sources for informational functions. We don't declare possession of the...